Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Octreotide
Octreotide
Routinely available
Local application
30/11/2022
Indication
In high output stoma and enterocutaneous fistula, to reduce output when other means have failed (loperamide, codeine, proton pump inhibitor and fluid restriction).
Therapeutic Area
Gastro-intestinal system
Status Description
Routinely available in line with local or regional guidance
Formulation
50 or 100 micrograms/1ml solution for injection ampoules and prefilled syringes
Comments
November 2022 - Routinely available in line with local or regional guidance. Included on the ERF for Specialist Initiation. Classified for use under policy for the use of unlicensed medicines.